The Pancreatic Tumor drugs in development market research report provides comprehensive information on the therapeutics under development for Pancreatic Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Pancreatic Tumor. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Pancreatic Tumor and features dormant and discontinued products.
GlobalData tracks 16 drugs in development for Pancreatic Tumor by 16 companies/universities/institutes. The top development phase for Pancreatic Tumor is preclinical with seven drugs in that stage. The Pancreatic Tumor pipeline has 14 drugs in development by companies and two by universities/ institutes. Some of the companies in the Pancreatic Tumor pipeline products market are: Amgen, Vanquish Oncology and Pfizer.
The key targets in the Pancreatic Tumor pipeline products market include DNA, Endothelial PAS Domain Containing Protein 1, and CD276 Antigen.
The key mechanisms of action in the Pancreatic Tumor pipeline product include DNA Synthesis Inhibitor with two drugs in Phase II. The Pancreatic Tumor pipeline products include five routes of administration with the top ROA being Intravenous and seven key molecule types in the Pancreatic Tumor pipeline products market including Small Molecule, and Monoclonal Antibody.
Pancreatic Tumor overview
Pancreatic cancer refers to the carcinoma arising from the pancreatic duct cells. Small changes in the cellular DNA result in uncontrolled multiplication and accumulation of cells into a tumor. Signs and symptoms of the most common form of pancreatic cancer may include yellow skin, abdominal or back pain, unexplained weight loss, light-colored stools, dark urine, and loss of appetite. Surgical resection is the only current option for a cure, but only 20% of pancreatic cancer is surgically resectable at the time of diagnosis.
For a complete picture of Pancreatic Tumor’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
